DK3401334T3 - Monoklonale antistoffer mod claudin-18 til cancerbehandling - Google Patents

Monoklonale antistoffer mod claudin-18 til cancerbehandling Download PDF

Info

Publication number
DK3401334T3
DK3401334T3 DK18168460.6T DK18168460T DK3401334T3 DK 3401334 T3 DK3401334 T3 DK 3401334T3 DK 18168460 T DK18168460 T DK 18168460T DK 3401334 T3 DK3401334 T3 DK 3401334T3
Authority
DK
Denmark
Prior art keywords
monoclonal antibodies
antibodies against
cancer treatment
against claudin
claudin
Prior art date
Application number
DK18168460.6T
Other languages
English (en)
Other versions
DK3401334T5 (da
Inventor
Ugur Sahin
Özlem Türeci
Gunda Brandenburg
Dirk Usener
Original Assignee
Astellas Pharma Inc
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Astellas Pharma Inc
Publication of DK3401334T3 publication Critical patent/DK3401334T3/da
Application granted granted Critical
Publication of DK3401334T5 publication Critical patent/DK3401334T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK18168460.6T 2007-05-29 2008-05-27 Monoklonale antistoffer mod claudin-18 til cancerbehandling DK3401334T5 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93209907P 2007-05-29 2007-05-29
EP07010622A EP1997832A1 (en) 2007-05-29 2007-05-29 Monoclonal antibodies against Claudin-18 for treatment of cancer
EP08758782.0A EP2152754B8 (en) 2007-05-29 2008-05-27 Monoclonal antibodies against claudin-18 for treatment of cancer

Publications (2)

Publication Number Publication Date
DK3401334T3 true DK3401334T3 (da) 2023-03-27
DK3401334T5 DK3401334T5 (da) 2024-09-23

Family

ID=38650052

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18168460.6T DK3401334T5 (da) 2007-05-29 2008-05-27 Monoklonale antistoffer mod claudin-18 til cancerbehandling

Country Status (24)

Country Link
US (1) US8425902B2 (da)
EP (4) EP1997832A1 (da)
JP (3) JP5816431B2 (da)
KR (3) KR101693365B1 (da)
CN (2) CN101687929B (da)
BR (1) BRPI0811907A2 (da)
CA (1) CA2687206C (da)
DK (1) DK3401334T5 (da)
ES (2) ES2940775T3 (da)
FI (1) FI3401334T3 (da)
HR (1) HRP20230282T3 (da)
HU (1) HUE061795T2 (da)
IL (3) IL201666A (da)
LT (1) LT3401334T (da)
MX (1) MX2009012906A (da)
NZ (1) NZ581365A (da)
PL (1) PL3401334T3 (da)
PT (1) PT3401334T (da)
RS (1) RS64065B1 (da)
RU (2) RU2571923C2 (da)
SG (1) SG183773A1 (da)
SI (1) SI3401334T1 (da)
WO (1) WO2008145338A2 (da)
ZA (1) ZA200907675B (da)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ド読取装置
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) * 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
WO2009086197A1 (en) 2007-12-20 2009-07-09 Monogram Biosciences, Inc. Her-2 diagnostic methods
EP2282769A4 (en) 2008-04-29 2012-04-25 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
KR20110016959A (ko) 2008-06-03 2011-02-18 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
EP2438442B1 (en) 2008-12-01 2017-08-09 Laboratory Corporation of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
BRPI1007321A2 (en) 2009-01-15 2018-07-10 Laboratory Corporation Of America Holdings methods for measuring and / or quantifying the presence and / or amount of her-3 or her-3 in a complex in a patient sample, and to determine if an individual with cancer is likely to respond to treatment with a targeted therapy. and antibody.
MX2011008430A (es) 2009-02-20 2011-09-29 Ganymed Pharmaceuticals Ag Metodos y composiciones para diagnostico y tratamiento del cancer.
BRPI1012195A2 (en) * 2009-05-01 2018-04-24 Abbott Laboratories double variable domain immunoglobulins and their uses
MX2012002651A (es) 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
AR078651A1 (es) 2009-10-15 2011-11-23 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3689911B1 (en) 2009-11-11 2024-08-21 Astellas Pharma Inc. Antibodies specific for claudin 6 (cldn6)
US8840902B2 (en) 2010-03-16 2014-09-23 Biontech Ag Tumor vaccination involving a humoral immune response against self-proteins
EP2366709A1 (en) * 2010-03-16 2011-09-21 BioNTech AG Tumor vaccination involving a humoral immune response against self-proteins
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CA2826563C (en) * 2011-02-07 2020-10-20 Paul Kussie Methods and systems for treating eclampsia and pre-eclampsia
KR102037432B1 (ko) * 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
EP3026064B1 (en) 2011-05-13 2018-10-17 Ganymed Pharmaceuticals GmbH Antibodies for treatment of cancer expressing claudin 6
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
WO2013167153A1 (en) * 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
EP2852409B1 (en) 2012-05-23 2020-03-25 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174403A1 (en) * 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
DK3254695T3 (da) * 2012-05-23 2020-11-30 Astellas Pharma Inc Kombinationsterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer
CA2888763A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
IL282953B2 (en) * 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for the treatment of claudin-expressing cancers
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP4177273A1 (en) * 2013-02-20 2023-05-10 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
WO2014146672A1 (en) * 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CN120329449A (zh) * 2014-07-17 2025-07-18 恺兴生命科技(上海)有限公司 靶向cld18a2的t淋巴细胞及其制备方法和应用
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
WO2016180468A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Claudin-18.2-specific immunoreceptors and t cell epitopes
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN118165113B (zh) * 2016-04-26 2025-10-28 恺兴生命科技(上海)有限公司 一种改善免疫应答细胞功能的方法
EP3538141A4 (en) * 2016-11-10 2020-07-15 Merck Sharp & Dohme Corp. LIGAND ILT3
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2018148595A1 (en) * 2017-02-10 2018-08-16 Washington University Antibodies to tip1 and methods of use thereof
US20180298094A1 (en) * 2017-04-17 2018-10-18 Ksl Biomedical Llc Monoclonal antibodies targeted to human taxilin alpha and methods for use of same
EP3613771A4 (en) * 2017-04-18 2021-08-04 Good T Cells, Inc. SPECIFIC LRIG-1 PROTEIN BINDING MOLECULE AND ITS USE
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
CN107779500A (zh) * 2017-10-25 2018-03-09 上海药明生物技术有限公司 一种快速获取大鼠杂交瘤细胞单克隆抗体序列的测序方法及引物序列
MX2020009326A (es) 2018-03-08 2020-10-08 Phanes Therapeutics Inc Anticuerpos anti-claudina 18.2 y usos de los mismos.
CN112020516B (zh) * 2018-03-13 2025-01-03 塔斯克疗法有限公司 用于肿瘤特异性细胞清除的抗-cd25
CA3087423A1 (en) * 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
CN110862454B (zh) * 2018-08-27 2022-12-30 南京圣和药业股份有限公司 一种抗Claudin18_2抗体及其应用
US20210380680A1 (en) * 2018-12-07 2021-12-09 ZLlP HOLDING LIMITED Anti-claudin antibodies and uses thereof
KR20210109520A (ko) 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 및 이의 용도
MX2021007939A (es) * 2018-12-28 2021-10-22 Nanjing Genscript Biotech Co Ltd Porciones de union a claudina 18.2 y usos de estas.
CN114106183B (zh) * 2019-01-15 2023-06-23 浙江道尔生物科技有限公司 抗cld18a2纳米抗体及其应用
CN109762067B (zh) * 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
JP7840511B2 (ja) * 2019-02-01 2026-04-06 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗クローディン１８抗体及びそれらの使用の方法
MX2021011489A (es) * 2019-04-01 2021-10-22 Jiangsu Hengrui Medicine Co Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
CN111978402B (zh) * 2019-05-24 2022-06-28 三优生物医药(上海)有限公司 新型cldn18.2结合分子
CA3141504A1 (en) 2019-05-24 2020-12-03 Sanyou Biopharmaceuticals Co., Ltd. Novel cldn18.2 binding molecule
CN114364701A (zh) * 2019-07-17 2022-04-15 加利福尼亚大学董事会 密封蛋白18抗体和治疗癌症的方法
CN114630840B (zh) * 2019-08-20 2024-08-02 苏州创胜医药集团有限公司 新型抗cldn18.2抗体
CN112574307B (zh) * 2019-09-29 2023-11-28 迈威(上海)生物科技股份有限公司 抗人Claudin18.2抗体及其应用
AU2020378502A1 (en) 2019-11-05 2022-06-16 LaNova Medicines Limited Antibody-drug conjugates targeting claudin 18.2
JP7641967B2 (ja) * 2019-12-06 2025-03-07 ソティオ バイオテック エイ．エス． ヒト化ｃｌｄｎ１８．２抗体
BR112022012327A2 (pt) 2019-12-23 2022-10-18 Sotio Biotech A S Anticorpos ou fragmentos dos mesmos, ácido nucleico, vetor e célula hospedeira
AU2021204861B2 (en) * 2020-01-03 2024-10-17 Crage Medical Co., Limited Anti-claudin 18.2 antibody and use thereof
AU2021250814A1 (en) 2020-03-30 2022-10-13 BioNTech SE RNA compositions targeting Claudin-18.2
CN113493515B (zh) * 2020-04-02 2023-03-28 广东菲鹏制药股份有限公司 抗cldn18a2的抗体以及治疗肿瘤的药物
CR20220580A (es) * 2020-05-15 2023-04-11 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo
CN111808194B (zh) * 2020-07-13 2021-04-20 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
WO2022011531A1 (zh) * 2020-07-14 2022-01-20 浙江道尔生物科技有限公司 一种抗cld18a2的单域抗体
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
US20240043529A1 (en) * 2020-12-22 2024-02-08 Eutropics Pharmaceuticals, Inc. Methods and compositions related to bcl2 and bim heterodimer antibodies
KR20230124037A (ko) 2020-12-23 2023-08-24 소티오 바이오테크 에이.에스. 종양 특이적 claudin 18.2 항체-약물 접합체
EP4347663A4 (en) * 2021-05-31 2025-05-14 Shijiazhuang Yiling Pharmaceutical Co., Ltd. MONOCLONAL ANTIBODIES AGAINST CLDN18.2 AND THEIR FC-MODIFIED VERSIONS
IL314678A (en) 2022-02-27 2024-10-01 Boehringer Ingelheim Int Bispecific antibodies against cd277 and a tumor-antigen
CN114836388A (zh) * 2022-06-07 2022-08-02 江苏亲科生物研究中心有限公司 Claudin18.2单克隆抗体及其制备方法和用途
WO2024074211A1 (en) 2022-10-06 2024-04-11 BioNTech SE Rna compositions targeting claudin-18.2
CN120129702A (zh) 2022-10-06 2025-06-10 生物技术公司 靶向密蛋白-18.2的rna组合物
CN119462924A (zh) * 2023-08-10 2025-02-18 东莞市朋志生物科技有限公司 一种抗胃泌素17抗体及其应用
WO2026062193A1 (en) 2024-09-20 2026-03-26 BioNTech SE Compositions and methods

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
WO1991009974A1 (en) 1989-12-27 1991-07-11 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Diagnostic probe for detecting human stomach cancer
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL154751A0 (en) 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2003106497A1 (en) * 2002-06-14 2003-12-24 Immunomedics, Inc. Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer
CA2832136C (en) * 2002-09-27 2015-11-17 Xencor Optimized fc variants and methods for their generation
KR100944575B1 (ko) 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US20050255041A1 (en) 2004-05-13 2005-11-17 Arius Research, Inc. Cancerous disease modifying antibodies
EP1954272A2 (en) * 2005-10-31 2008-08-13 Bayer Pharmaceuticals Corporation Treatment of cancer with sorafenib
EP1790664A1 (en) * 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer

Also Published As

Publication number Publication date
JP2010528075A (ja) 2010-08-19
RU2015149617A3 (da) 2019-02-04
WO2008145338A2 (en) 2008-12-04
SI3401334T1 (sl) 2023-05-31
HUE061795T2 (hu) 2023-08-28
CN103694353B (zh) 2017-12-12
ES2675375T3 (es) 2018-07-10
KR101693365B1 (ko) 2017-01-06
JP2015007053A (ja) 2015-01-15
EP3401334B1 (en) 2023-02-15
KR101751965B1 (ko) 2017-07-11
EP2152754B8 (en) 2018-07-04
MX2009012906A (es) 2010-01-25
KR20100021573A (ko) 2010-02-25
EP1997832A1 (en) 2008-12-03
CN101687929A (zh) 2010-03-31
RU2571923C2 (ru) 2015-12-27
EP4242236A3 (en) 2023-11-22
SG183773A1 (en) 2012-09-27
JP6337053B2 (ja) 2018-06-06
ZA200907675B (en) 2011-04-28
FI3401334T3 (fi) 2023-03-17
KR101585990B1 (ko) 2016-01-19
CA2687206A1 (en) 2008-12-04
CN103694353A (zh) 2014-04-02
AU2008256489A1 (en) 2008-12-04
EP4242236A2 (en) 2023-09-13
JP2017048170A (ja) 2017-03-09
PL3401334T3 (pl) 2023-05-15
PT3401334T (pt) 2023-03-27
US8425902B2 (en) 2013-04-23
RU2015149617A (ru) 2019-01-14
KR20150023951A (ko) 2015-03-05
RU2682285C2 (ru) 2019-03-18
BRPI0811907A2 (pt) 2014-11-18
ES2940775T3 (es) 2023-05-11
CN101687929B (zh) 2013-11-13
JP5816431B2 (ja) 2015-11-18
IL238667A0 (en) 2015-06-30
IL238668A0 (en) 2015-06-30
EP2152754A2 (en) 2010-02-17
NZ581365A (en) 2012-02-24
RU2009149205A (ru) 2011-07-10
KR20170005160A (ko) 2017-01-11
RS64065B1 (sr) 2023-04-28
CA2687206C (en) 2019-07-16
US20100166779A1 (en) 2010-07-01
IL201666A (en) 2016-03-31
IL201666A0 (en) 2010-05-31
WO2008145338A3 (en) 2009-02-12
HRP20230282T3 (hr) 2023-05-12
LT3401334T (lt) 2023-03-27
DK3401334T5 (da) 2024-09-23
EP2152754B1 (en) 2018-04-25
JP5995919B2 (ja) 2016-09-21
EP3401334A1 (en) 2018-11-14

Similar Documents

Publication Publication Date Title
DK3401334T5 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
DK3656793T3 (da) Monoklonale antistoffer mod claudin-18 til cancerbehandling
LTC2076540I2 (lt) Nauji anti-cd38 antikūnai, skirti vėžio gydymui
BRPI0918178A2 (pt) anticorpos monoclonais para tratamento de câncer
IL243376A0 (en) Antagonist antibody against epha2 for the treatment of cancer
PT2242773T (pt) Anticorpos monoclonais para o tratamento de tumores
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
HRP20180485T1 (hr) Monoklonska antitijela za gt468 za liječenje raka
NO344963B1 (no) Humanisert antistoff
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
BRPI0814111A2 (pt) Anticorpo monoclonal citotóxico anticâncer
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
BRPI0815399A2 (pt) tratamento de câncer usando anticorpos humanizados que se ligam ephb4
DK2094728T3 (da) Fremgangsmåder til anvendelse for human-adapterende monoklonale antistoffer
BRPI0814116A2 (pt) Anticorpo monoclonal citotóxico anticâncer
BRPI0813520A2 (pt) Anticorpo monoclonal citotóxico anticâncer
IL207478A0 (en) Monoclonal antibodies for tumor treatment